CA2453442C - Compositions et methodes d'administration d'agents de fixation a la tubuline dans le traitement de maladies oculaires - Google Patents

Compositions et methodes d'administration d'agents de fixation a la tubuline dans le traitement de maladies oculaires Download PDF

Info

Publication number
CA2453442C
CA2453442C CA2453442A CA2453442A CA2453442C CA 2453442 C CA2453442 C CA 2453442C CA 2453442 A CA2453442 A CA 2453442A CA 2453442 A CA2453442 A CA 2453442A CA 2453442 C CA2453442 C CA 2453442C
Authority
CA
Canada
Prior art keywords
recited
ocular
subject
combretastatin
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2453442A
Other languages
English (en)
Other versions
CA2453442A1 (fr
Inventor
David Sherris
Mark Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxi Gene Inc
Original Assignee
Oxi Gene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxi Gene Inc filed Critical Oxi Gene Inc
Publication of CA2453442A1 publication Critical patent/CA2453442A1/fr
Application granted granted Critical
Publication of CA2453442C publication Critical patent/CA2453442C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne l'administration d'agents de ciblage vasculaire, en particulier des agents de fixation à la tubuline, dans le traitement de la néovascularisation oculaire, des tumeurs oculaires, et des troubles tels que la rétinopathie diabétique, la rétinopathie de prématurité, le rétinoblastome et la dégénérescence maculaire.
CA2453442A 2001-07-13 2002-07-15 Compositions et methodes d'administration d'agents de fixation a la tubuline dans le traitement de maladies oculaires Expired - Fee Related CA2453442C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US38622701P 2001-07-13 2001-07-13
US60/386,227 2001-07-13
US37784702P 2002-05-03 2002-05-03
US37755602P 2002-05-03 2002-05-03
US37784502P 2002-05-03 2002-05-03
US60/377,556 2002-05-03
US60/377,845 2002-05-03
US60/377,847 2002-05-03
PCT/US2002/022449 WO2003006002A1 (fr) 2001-07-13 2002-07-15 Compositions et methodes d'administration d'agents de fixation a la tubuline dans le traitement de maladies oculaires

Publications (2)

Publication Number Publication Date
CA2453442A1 CA2453442A1 (fr) 2003-01-23
CA2453442C true CA2453442C (fr) 2011-02-01

Family

ID=32034390

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2453442A Expired - Fee Related CA2453442C (fr) 2001-07-13 2002-07-15 Compositions et methodes d'administration d'agents de fixation a la tubuline dans le traitement de maladies oculaires

Country Status (8)

Country Link
EP (1) EP1406600A4 (fr)
JP (2) JP2004536847A (fr)
KR (1) KR20040030042A (fr)
CN (1) CN1527704B (fr)
CA (1) CA2453442C (fr)
NZ (1) NZ575466A (fr)
WO (1) WO2003006002A1 (fr)
ZA (1) ZA200400210B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
JP4005048B2 (ja) * 2003-04-09 2007-11-07 日信工業株式会社 炭素繊維複合材料およびその製造方法
AU2010266109A1 (en) * 2009-07-02 2012-02-02 Oxigene, Inc. Combretastatins for prevention of posterior capsule opacification
JP6141016B2 (ja) 2009-08-27 2017-06-07 バイオノミックス リミテッド 増殖性疾患の治療のための併用療法
AU2010286343B2 (en) * 2009-08-27 2016-08-04 Bionomics Limited Treatment of macular degeneration
AP2015008241A0 (en) * 2012-08-02 2015-01-31 Amril Ag Natural rubber containing nanocarbon
CN113520995B (zh) * 2021-08-16 2023-03-10 海南鑫开源医药科技有限公司 一种离子敏感型眼用原位凝胶、其制备方法及应用
CN113577020B (zh) * 2021-08-16 2022-09-23 海南鑫开源医药科技有限公司 一种玻璃体腔内注射剂、其制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (fr) * 1987-01-06 1996-10-15 George R. Pettit Isolation, caracterisation structurelle et synthese de nouvelles substances antineoplastiques, appelees "combretastatines"
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
CA2314238C (fr) * 1998-01-09 2008-09-02 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthese de promedicaments a base de combrestatine a-4 et de leurs trans-isomeres
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
US6538038B1 (en) * 1999-02-18 2003-03-25 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts

Also Published As

Publication number Publication date
WO2003006002A8 (fr) 2004-05-27
NZ575466A (en) 2011-01-28
CA2453442A1 (fr) 2003-01-23
JP2009132738A (ja) 2009-06-18
WO2003006002A9 (fr) 2004-07-22
WO2003006002A1 (fr) 2003-01-23
EP1406600A4 (fr) 2007-06-06
ZA200400210B (en) 2005-06-29
JP2004536847A (ja) 2004-12-09
CN1527704A (zh) 2004-09-08
CN1527704B (zh) 2011-05-18
EP1406600A1 (fr) 2004-04-14
KR20040030042A (ko) 2004-04-08

Similar Documents

Publication Publication Date Title
US20030181531A1 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
JP2009132738A (ja) 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法
US20040229960A1 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US6524330B1 (en) Method of ocular treatment
EP1476147A1 (fr) Methodes de traitement de troubles de la vue
US20020161013A1 (en) Method of local anesthesia and analgesia
US8691874B2 (en) Treatment of ophthalmic disorders using urea
US20100190734A1 (en) Method of treating dry eye disease with azithromycin
ZA200510344B (en) Coumarin derivatives for the treatment of ophthalmic disorders
WO2002043722A2 (fr) Agents de chelation de cuivre servant a traiter l'inflammation oculaire
AU2008202468B2 (en) Compositions and Methods of Administering Tubulin Binding Agents for the Treatment of Ocular Diseases
US20030007971A1 (en) Remedies for ophthalmic diseases
US8679557B2 (en) Synergistic herbal ophthalmic formulation for lowering the intra ocular pressure in case of glaucoma
RU2354398C2 (ru) Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний
AU2002322494A1 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
EP1480678B1 (fr) Traitement des troubles ophtalmiques avec de l'uree ou des derives d'uree
JP2004331502A (ja) 視神経細胞保護剤
WO2001056606A1 (fr) Remedes pour troubles ophtalmiques
JP4393863B2 (ja) 視神経細胞保護剤
US20100331311A1 (en) Galantamine as a neuroprotective drug for retinal ganglion cells
RU2458657C1 (ru) Способ торможения грубого рубцевания конъюнктивы

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170717